UBS Upgrades Illumina to Buy From Neutral, Adjusts Price Target to $260 From $135

UBS upgraded Illumina to 'Buy' from 'Neutral' and raised its price target to $260 from $135. Illumina's stock is currently trading at $208.12, down 1.40% for the day and 2.64% for the year, but up 58.30% over a longer period. The company is set to join the S&P 500 in September.

Original reporting
Published Sep 9, 2026, 1:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 5:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ILMN
Bullish
high confidence
Mentioned
$ILMN
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$ILMNBullishMed
01

Why it matters

The upgrade is likely to attract buying interest and could trigger short covering.

02

Market read

Analyst upgrade may move Illumina stock in early trading.

03

What to watch

Potential regulatory or reimbursement challenges could temper upside.

Relevance 7/10Novelty 7/10Timing: pre-market today

Background

UBS issued a new rating and price target for Illumina, reflecting its revised outlook.

Company-level read

Ticker impact

$ILMNBullishHigh confidence
Context

UBS upgraded Illumina to Buy and raised its price target to $260 from $135.

Expected impact

upward pressure on ILMN price

Evidence & confidence

Upgrade and higher target reflect improved valuation expectations.

Market effects

May boost sentiment in the genomics/biotech sector.

Limited to US markets where Illumina trades.

Minor, primarily affects investors tracking biotech equities.

Counterpoint

Some analysts may view the target increase as overly optimistic given competitive pressures.

Key entities

  • Illumina

    Genomics sequencing company.

  • UBS

    Financial services firm providing the upgrade.

Related articles

$ILMNHighAI 8/10

Dear Illumina Stock Fans, Mark Your Calendars for September 21

Illumina raised its full-year 2026 guidance, expecting revenue of $4.60B-$4.64B and EPS of $5.30-$5.40, citing strong clinical consumables growth and momentum in multiomics. The company also announced new leadership and partnerships. Analysts project revenue growth to $6B by 2030, with mixed stock ratings and an average price target of $207.21.

$BEHighAI 8/10

Bloom Energy’s S&P 500 Entry Could Bring A New Wave Of Buyers, Says Clear Street — Projects 20% Upside In BE Stock

Bloom Energy (BE) will join the S&P 500 on September 21, according to S&P Dow Jones Indices. Clear Street raised its price target to $330, citing 20% upside potential and expected institutional investor interest. BE stock gained 9% on the news. UBS also raised its target to $325. Bloom reported record Q2 revenue and raised its 2026 outlook to $3.9B-$4.2B.

$TTDLow

Trade Desk loses S&P 500 seat the same day 575 jobs end

The Trade Desk (TTD) was removed from the S&P 500 index and laid off 575 employees on the same day. Illumina (ILMN) will replace it. The stock fell 4.37% to $14.43, down 90% since its inclusion in July 2025. The company reported slowing growth and leadership changes.

$ILMNMedAI 8/10

Illumina joins S&P 500 as Bloom Energy, Everpure also added

Illumina (ILMN), Bloom Energy (BE), and Everpure (P) will join the S&P 500 on 21 September 2026, replacing Molson Coors (TAP), The Trade Desk (TTD), and Builders FirstSource (BLDR). All three stocks gained in after-hours trading, with Bloom Energy rising up to 7.5%. Illumina reported $1.159B revenue for Q2 2026, up from $1.059B a year earlier, and improved earnings per share. Bloom Energy has seen a 191% rally over the past year, driven by AI data-center demand.